BioNTech (NASDAQ:BNTX) Shares Up 4.4% - Should You Buy?

Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) traded up 4.4% on Friday . The stock traded as high as $125.40 and last traded at $124.08. 419,270 shares changed hands during trading, a decline of 48% from the average session volume of 809,889 shares. The stock had previously closed at $118.84.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. BMO Capital Markets restated an "outperform" rating on shares of BioNTech in a report on Monday. Morgan Stanley upgraded shares of BioNTech from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. TD Cowen lowered their price objective on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research note on Tuesday, November 5th. Bank of America boosted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a report on Monday, September 16th. Finally, Evercore ISI upgraded BioNTech from an "in-line" rating to an "outperform" rating and raised their target price for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $138.67.

BioNTech Price Performance

The company has a market cap of $29.34 billion, a price-to-earnings ratio of -59.09 and a beta of 0.22. The company's 50 day moving average price is $113.84 and its 200 day moving average price is $99.36. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech's quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.73 earnings per share. Equities research analysts forecast that BioNTech SE will post -3.72 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently bought and sold shares of BNTX. FMR LLC boosted its holdings in shares of BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after purchasing an additional 5,598,190 shares during the last quarter. Fred Alger Management LLC purchased a new position in BioNTech during the third quarter worth about $59,485,000. Candriam S.C.A. boosted its stake in BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after buying an additional 418,695 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock valued at $37,103,000 after buying an additional 341,311 shares during the period. Finally, Braidwell LP acquired a new position in shares of BioNTech during the 3rd quarter valued at about $29,425,000. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.